NASDAQ:CBIO

Catalyst Biosciences Stock Forecast, Price & News

$4.14
-0.09 (-2.13 %)
(As of 07/27/2021 04:30 PM ET)
Add
Compare
Today's Range
$4.11
$4.28
50-Day Range
$4.10
$4.65
52-Week Range
$4.05
$7.55
Volume130,996 shs
Average Volume392,276 shs
Market Capitalization$129.79 million
P/E RatioN/A
Dividend YieldN/A
Beta2.02
30 days | 90 days | 365 days | Advanced Chart
Receive CBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Catalyst Biosciences logo

About Catalyst Biosciences

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. The company's pipeline also includes a preclinical program partnered with Biogen International GmbH for dry age-related macular degeneration (AMD); factor I protease for SQ prophylaxis in patients with complement factor I deficiency and C4b-degraders designed to target disorders of the classical complement pathway, as well as other complement programs. The company also develops CB 4332 intended for lifelong prophylactic SQ administration in individuals with CFI deficiency; and CB 2782-PEG, a C3 degrader product candidate in preclinical development for the treatment of dry AMD. It has a strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases; and license and collaboration agreement with Biogen International GmbH for the development and commercialization of pegylated CB 2782 (anti-C3 protease) to treat geographic atrophy associated dry AMD. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.84 out of 5 stars

Medical Sector

345th out of 2,218 stocks

Pharmaceutical Preparations Industry

161st out of 869 stocks

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions

Is Catalyst Biosciences a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Catalyst Biosciences stock.
View analyst ratings for Catalyst Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Catalyst Biosciences?

Wall Street analysts have given Catalyst Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Catalyst Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Catalyst Biosciences?

Catalyst Biosciences saw a decline in short interest in the month of June. As of June 30th, there was short interest totaling 885,200 shares, a decline of 44.3% from the June 15th total of 1,590,000 shares. Based on an average daily volume of 326,800 shares, the days-to-cover ratio is presently 2.7 days. Approximately 2.9% of the company's shares are sold short.
View Catalyst Biosciences' Short Interest
.

When is Catalyst Biosciences' next earnings date?

Catalyst Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Catalyst Biosciences
.

How were Catalyst Biosciences' earnings last quarter?

Catalyst Biosciences, Inc. (NASDAQ:CBIO) released its quarterly earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.58) by $0.21. The biopharmaceutical company earned $1.47 million during the quarter, compared to the consensus estimate of $1 million. Catalyst Biosciences had a negative trailing twelve-month return on equity of 77.89% and a negative net margin of 1,233.58%.
View Catalyst Biosciences' earnings history
.

How has Catalyst Biosciences' stock been impacted by Coronavirus?

Catalyst Biosciences' stock was trading at $4.83 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CBIO shares have decreased by 14.3% and is now trading at $4.14.
View which stocks have been most impacted by COVID-19
.

When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?

Catalyst Biosciences's stock reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CBIO?

5 brokers have issued twelve-month target prices for Catalyst Biosciences' stock. Their forecasts range from $4.31 to $18.00. On average, they anticipate Catalyst Biosciences' stock price to reach $12.44 in the next year. This suggests a possible upside of 200.4% from the stock's current price.
View analysts' price targets for Catalyst Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Catalyst Biosciences' key executives?

Catalyst Biosciences' management team includes the following people:
  • Dr. Nassim Usman, Pres, CEO & Director (Age 61, Pay $769.18k)
  • Mr. Clinton Musil, Chief Financial Officer (Age 40, Pay $468.46k)
  • Dr. Howard Levy, Chief Medical Officer (Age 67, Pay $577.04k)
  • Ms. Ana Kapor, Sr. Director of Investor Relations & Corp. Communications
  • Dr. Tom Knudsen D.V.M., Ph.D., VP of Corp. Devel.
  • Dr. Grant Blouse, Sr. VP of Translational Research
  • Mr. Charles J. Democko, Sr. VP of Regulatory Affairs & Quality (Age 66)
  • Dr. Anju Chatterji Ph.D., Sr. VP of Biologics Devel. & Manufacturing

Who are some of Catalyst Biosciences' key competitors?

What other stocks do shareholders of Catalyst Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Celsion (CLSN).

What is Catalyst Biosciences' stock symbol?

Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."

How do I buy shares of Catalyst Biosciences?

Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalyst Biosciences' stock price today?

One share of CBIO stock can currently be purchased for approximately $4.14.

How much money does Catalyst Biosciences make?

Catalyst Biosciences has a market capitalization of $129.79 million and generates $20.95 million in revenue each year. The biopharmaceutical company earns $-56,240,000.00 in net income (profit) each year or ($2.93) on an earnings per share basis.

How many employees does Catalyst Biosciences have?

Catalyst Biosciences employs 56 workers across the globe.

What is Catalyst Biosciences' official website?

The official website for Catalyst Biosciences is www.catalystbiosciences.com.

Where are Catalyst Biosciences' headquarters?

Catalyst Biosciences is headquartered at 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Catalyst Biosciences?

Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at (650) 871-0761 or via email at [email protected]


This page was last updated on 7/27/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.